Cagrilintide 5 mg
$80.00$34.00
Main Title
Cagrilintide 5 mg — Long-Acting Amylin & Calcitonin Receptor Agonist for Metabolic & Weight Management Research
Full Description
Cagrilintide is a synthetic long-acting acylated analog of human amylin (IAPP). It functions as a dual amylin receptor (AMYR) and calcitonin receptor (CTR) agonist. It is extensively investigated in preclinical and clinical research for its potent effects on satiety, gastric emptying, and energy balance, particularly in models of obesity and metabolic dysfunction, often studied in combination with GLP-1 receptor agonists.
What It Is
Class: Long-acting amylin/calcitonin receptor agonist (DACRA)
Concept: Mimics and prolongs the actions of endogenous amylin to enhance satiety signaling, slow gastric emptying, and support body weight regulation via central and peripheral pathways.
Format: Research-grade synthetic peptide supplied as a lyophilized powder.
Proposed Mechanisms (Preclinical)
Amylin & Calcitonin Receptor Activation
Binds with high affinity to amylin receptors (AMY1R, AMY2R, AMY3R) and calcitonin receptors (CTR), activating Gs-coupled cAMP signaling.
Modulates brainstem and hypothalamic circuits involved in appetite suppression and energy homeostasis.
Gastrointestinal & Satiety Effects
Delays gastric emptying and promotes feelings of fullness, reducing caloric intake in metabolic models.
Synergizes with GLP-1 pathways to enhance weight loss and glycemic control.
Metabolic Regulation
Investigated for effects on glucagon secretion, lipid metabolism, and preservation of lean mass during weight reduction.
Selected Research Highlights
Weight Management: Produced robust, dose-dependent reductions in body weight and fat mass in preclinical obesity models, with additive effects when combined with GLP-1 agonists.
Satiety & Food Intake: Demonstrated strong suppression of appetite and caloric intake via central amylin signaling pathways.
Glycemic Control: Studied for improvements in fasting glucose and insulin sensitivity in type 2 diabetes models.
Combination Therapy (CagriSema): Extensively evaluated alongside semaglutide, showing superior weight loss and cardiometabolic benefits compared to monotherapy.
Receptor Dynamics: Structural studies reveal distinct conformational changes at CTR and AMYR compared to native amylin.
Long-Acting Profile: Engineered with fatty acid acylation for prolonged pharmacokinetics suitable for once-weekly dosing in research settings.
Chemical & Handling Information
Type: Synthetic acylated amylin analog
Key Modifications: N-terminal lipidation (C20 fatty acid), stabilizing mutations (e.g., 14E/17R salt bridge, proline substitutions)
Sequence (simplified backbone): Based on human amylin with multiple substitutions and N-terminal acylation
Appearance: White to off-white lyophilized powder
Specifications
Peptide: Cagrilintide
Amount: 5 mg per vial
Form: Lyophilized powder
Purity: ≥99% (HPLC) – Certificate of Analysis available per lot
Packaging: Sealed vials suitable for standard laboratory handling
Storage & Stability
Store lyophilized vials in a cool, dry place protected from light.
Refrigeration or freezing of the lyophilized peptide is recommended for extended stability according to laboratory SOPs.
After reconstitution: Store at 2–8 °C for short-term use.
Long-term storage: Aliquot and freeze at –20 °C or below. Avoid repeated freeze-thaw cycles.